{"id":3230,"count":51,"description":"The MedsBase Diabetes parent catalogue groups all diabetes-related medications across the major drug classes. The detailed clinical breakdown by molecule family with full brand listing is in our <a href=\"https:\/\/medsbase.com\/cs\/diabetes-medication\/\">L\u00e9ky na diabetes<\/a> sub-category \u2014 please browse there for selection guidance and dosing context. All products are supplied by <strong>WHO-GMP certifikovan\u00fdch v\u00fdrobc\u016f<\/strong>.\n\n<strong>Drug-class summary.<\/strong> Biguanides (metformin \u2014 first-line, Glycomet SR, Metford), sulfonylureas (gliclazide, glimepiride, glibenclamide, glipizide), DPP-4 inhibitors (sitagliptin Januvia, vildagliptin Galvus, saxagliptin Onglyza, linagliptin Trajenta, teneligliptin Ziten), SGLT-2 inhibitors (dapagliflozin Forxiga, empagliflozin Jardiance, canagliflozin Invokana \u2014 with cardio-renal protection benefits), pioglitazone (Pioz), meglitinides (repaglinide Novonorm, nateglinide Glinate), alpha-glucosidase inhibitors (acarbose Glucobay, voglibose Voglibite, miglitol Mignar), and rapid-acting insulin pens (insulin aspart Novorapid Flexpen, insulin glulisine Apidra SoloStar). Combination therapies pairing metformin with sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor reduce pill burden in poly-pharmacy patients.\n\n<strong>Specialty agents.<\/strong> Lipaglyn (saroglitazar \u2014 dual PPAR \u03b1\/\u03b3 agonist for diabetic dyslipidaemia and NASH) as <a href=\"https:\/\/medsbase.com\/cs\/lipaglyn\/\">Lipaglyn<\/a>. Methycobalamin \/ cyanocobalamin injections for diabetic neuropathy as <a href=\"https:\/\/medsbase.com\/cs\/methycobal-injection\/\">Methycobal Injekce<\/a>.\n\n<strong>What is NOT here.<\/strong> GLP-1 receptor agonists (semaglutide Ozempic, liraglutide Victoza, dulaglutide, tirzepatide) are stocked separately as part of our weight-management ordering \u2014 see <a href=\"https:\/\/medsbase.com\/cs\/how-to-get-ozempic-for-weight-loss\/\">Nejlep\u0161\u00ed alternativy Ozempicu 2026<\/a>. Long-acting basal insulins (insulin glargine, degludec, detemir) are listed in dedicated insulin sub-categories where in stock.\n\n<strong>Disambiguation.<\/strong> Desmopressin (Minirin tablet, Minirin Nasal Spray) is currently mis-listed in our diabetes catalogue. Desmopressin treats diabetes <strong>insipidus<\/strong> (a kidney disorder of water handling) and bedwetting \/ nocturia \u2014 NOT diabetes <strong>mellitus<\/strong> (the common type 1 \/ type 2 diabetes). Pages explicitly clarify this. Please move to the bladder-prostate \/ urology category once a dedicated bedwetting category exists.\n\n<strong>Jak vybrat.<\/strong> Type 2 diabetes new diagnosis \u2192 metformin first-line (titrate to 1.5\u20132 g\/day in divided doses). Inadequate control on metformin \u2192 add SGLT-2 inhibitor (cardio-renal benefit) or DPP-4 inhibitor (weight-neutral) or sulfonylurea (cheapest, hypoglycaemia risk). Established cardiovascular disease or heart failure \u2192 SGLT-2 inhibitor preferred regardless of HbA1c. Significant weight excess \u2192 SGLT-2 or GLP-1 RA. Hypoglycaemia risk (elderly, frail, lone) \u2192 avoid sulfonylureas, prefer DPP-4 inhibitors or SGLT-2. Type 1 diabetes \u2192 basal-bolus insulin regimen (specialist-initiated, not catalogued here).\n\n<strong>D\u016fle\u017eit\u00e9.<\/strong> Sudden hyperglycaemia with nausea, vomiting, abdominal pain \u2192 check for diabetic ketoacidosis (especially type 1 or SGLT-2 inhibitor user), urgent assessment. Severe hypoglycaemia with reduced consciousness \u2192 glucose \/ glucagon, 999. New diagnosis or significant control change requires HbA1c monitoring at 3 months. Lifestyle (diet, weight, activity, smoking cessation, BP and lipid control) remains the foundation of all diabetes care.\n\nAll MedsBase Diabetes products ship from <strong>WHO-GMP certifikovan\u00fdch v\u00fdrobc\u016f<\/strong> s diskr\u00e9tn\u00edm balen\u00edm a jsou kryty na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.\n\n<!-- mb-hub-link --><strong>2026 buyer's guide:<\/strong> Prohl\u00e9dn\u011bte si n\u00e1\u0161 v\u00fdb\u011br <a href=\"\/cs\/best-diabetes-medications-2026\/\">Best Diabetes Medications 2026: 10 Top Picks Compared<\/a> pro se\u0159azen\u00e9 tipy, srovn\u00e1vac\u00ed tabulku, d\u00e1vkov\u00e1n\u00ed a zkratku k rozhodnut\u00ed.","link":"https:\/\/medsbase.com\/cs\/diabetes\/","name":"Diabetes","slug":"diabetes","taxonomy":"product_cat","parent":3223,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat\/3223"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product?product_cat=3230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}